JP2011526917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526917A5 JP2011526917A5 JP2011516831A JP2011516831A JP2011526917A5 JP 2011526917 A5 JP2011526917 A5 JP 2011526917A5 JP 2011516831 A JP2011516831 A JP 2011516831A JP 2011516831 A JP2011516831 A JP 2011516831A JP 2011526917 A5 JP2011526917 A5 JP 2011526917A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- alkyl
- nrz
- nrc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 238000000034 method Methods 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7709108P | 2008-06-30 | 2008-06-30 | |
| US61/077,091 | 2008-06-30 | ||
| US15642609P | 2009-02-27 | 2009-02-27 | |
| US61/156,426 | 2009-02-27 | ||
| US18009509P | 2009-05-20 | 2009-05-20 | |
| US61/180,095 | 2009-05-20 | ||
| PCT/US2009/049318 WO2010002933A1 (en) | 2008-06-30 | 2009-06-30 | Oxindole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526917A JP2011526917A (ja) | 2011-10-20 |
| JP2011526917A5 true JP2011526917A5 (enExample) | 2012-08-16 |
Family
ID=41466309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516831A Pending JP2011526917A (ja) | 2008-06-30 | 2009-06-30 | オキシインドール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124649B2 (enExample) |
| EP (1) | EP2307421A4 (enExample) |
| JP (1) | JP2011526917A (enExample) |
| KR (1) | KR20110025996A (enExample) |
| CN (1) | CN102137866A (enExample) |
| AU (1) | AU2009267048A1 (enExample) |
| BR (1) | BRPI0914942A2 (enExample) |
| CA (1) | CA2729745A1 (enExample) |
| IL (1) | IL210355A0 (enExample) |
| MX (1) | MX2011000150A (enExample) |
| WO (1) | WO2010002933A1 (enExample) |
| ZA (1) | ZA201100539B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006467A (es) * | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
| CN102688234B (zh) * | 2011-03-21 | 2015-07-29 | 华东理工大学 | 吲哚酮衍生物作为rsk2抑制剂的合成与应用 |
| EP2688886A1 (en) | 2011-03-22 | 2014-01-29 | Amgen Inc. | Azole compounds as pim inhibitors |
| CN103509009A (zh) * | 2012-06-21 | 2014-01-15 | 中国科学院上海药物研究所 | 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途 |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| RS59220B1 (sr) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3187496A1 (de) | 2015-12-30 | 2017-07-05 | Heliatek GmbH | Verbindung für fotoaktive organische elektronische bauelemente und fotoaktives organisches elektronisches bauelement enthaltend die verbindung |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| WO2025085819A1 (en) * | 2023-10-18 | 2025-04-24 | Washington University | Kinase inhibitor compositions and related methods for the treatment of a disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US6846839B1 (en) * | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
| US20030119895A1 (en) * | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
| DE122008000002I1 (de) * | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| AU2002303892A1 (en) * | 2001-05-30 | 2002-12-09 | Jingrong Cui | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| AU2004284084A1 (en) * | 2003-10-24 | 2005-05-06 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| JP2007084494A (ja) * | 2005-09-22 | 2007-04-05 | Oncorex Inc | Ｐｉｍ−１活性阻害剤 |
| WO2007087419A2 (en) * | 2006-01-24 | 2007-08-02 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| WO2007087429A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| JP5256047B2 (ja) * | 2006-01-27 | 2013-08-07 | シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド | ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤 |
-
2009
- 2009-06-30 BR BRPI0914942-2A patent/BRPI0914942A2/pt not_active IP Right Cessation
- 2009-06-30 KR KR1020117002316A patent/KR20110025996A/ko not_active Withdrawn
- 2009-06-30 CN CN2009801336712A patent/CN102137866A/zh active Pending
- 2009-06-30 US US12/495,666 patent/US8124649B2/en not_active Expired - Fee Related
- 2009-06-30 EP EP09774383A patent/EP2307421A4/en not_active Withdrawn
- 2009-06-30 MX MX2011000150A patent/MX2011000150A/es not_active Application Discontinuation
- 2009-06-30 JP JP2011516831A patent/JP2011526917A/ja active Pending
- 2009-06-30 CA CA2729745A patent/CA2729745A1/en not_active Abandoned
- 2009-06-30 WO PCT/US2009/049318 patent/WO2010002933A1/en not_active Ceased
- 2009-06-30 AU AU2009267048A patent/AU2009267048A1/en not_active Withdrawn
-
2010
- 2010-12-29 IL IL210355A patent/IL210355A0/en unknown
-
2011
- 2011-01-20 ZA ZA2011/00539A patent/ZA201100539B/en unknown
-
2012
- 2012-01-20 US US13/354,563 patent/US20120190669A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526917A5 (enExample) | ||
| AU2023202592B2 (en) | Modulators of the integrated stress pathway | |
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| JP2008535903A5 (enExample) | ||
| JP6545199B2 (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| JP2008510828A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP6787899B2 (ja) | 医薬的活性化合物 | |
| JP2008535902A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| CA2769553A1 (en) | Novel pyrimidine and triazine hepcidin antagonists | |
| JP2009538897A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2013537198A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2011509301A5 (enExample) | ||
| JP2009539943A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| KR20140102200A (ko) | 약제학적 화합물 | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2010514734A5 (enExample) |